Skip to content Skip to footer

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)

IQI Blog

Langgan

Surat Berita

订阅我们的月讯

Subscribe to our

Newsletter